Fintel reports that on October 15, 2025, Baird upgraded their outlook for Vor Biopharma (NasdaqGS:VOR) from Neutral to ...

Shares of Vor Bio (Nasdaq: NASDAQ:VOR) rose after it reported that its partner, RemeGen (OTCPK:REGMF), met the main goal in a ...

The latest price target for Vor Biopharma (NASDAQ:VOR) was reported by Baird on October 15, 2025. The analyst firm set a price target for $64.00 expecting VOR to rise to within 12 months (a possible ...

Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from Stage A of a Phase 3 study in China sponsored ...

Investing.com -- Vor Biopharma Inc (NASDAQ:VOR) 股价在周二盘前交易中上涨3.8%，此前其合作伙伴荣昌生物 (RemeGen)报告了telitacicept在原发性干燥综合征三期研究中的48周积极结果。

Investing.com - 贝尔德 (Baird)周二将 Vor Biopharma, Inc. (NASDAQ:VOR) 的评级从"中性"上调至"优于大市"，同时大幅提高其目标价，从20.00美元上调至64.00美元。根据 InvestingPro 数据，该股票在过去六个月内已上涨超过120%，目前基于全面的公允价值分析显示其被低估。

Vor Biopharma has rebounded from near-delisting by securing global rights (ex-China) to telitacicept, a promising autoimmune therapy. VOR's telitacicept targets multi-billion dollar autoimmune markets ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Die Europäische Zentralbank steht vor einem zweijährigen Umbruch: Zwei Drittel der Führung werden ausgetauscht – darunter ...

The challenges facing biotechs amid the ongoing financial fallout have resulted in the winding down of one US biotech, Vor Bio, and job losses at a clutch of other firms. Cambridge, ...